Overview

AbCelex Technologies develops camelid antibody platforms and related therapeutic candidates. Its platform enables rational design and optimization of antibodies with extended half-life, greater proteolytic stability, and tailored binding strength, including orally delivered antibodies for infectious diseases demonstrated in two programs. It can rapidly assemble multi-specific and multivalent agents by interchanging antibody subunits, and it has expressed 50+ protein antigens with 10+ large libraries. Its goal is to advance these antibody technologies toward clinical development and broaden therapeutic applications, with one immuno-recruiting platform in early preclinical development.